DrugPatentWatch - Biopharmaceutical Business Intelligence
Profile for Coherus BioSciences, Inc. (CHRS)
« Back to company indexCHRS Chatter Timeline
Stock Ticker for CHRS
Most Active Tweeters for CHRS
| User | Tweets |
|---|---|
| @kshahi | 6 |
| @larrywabrams | 4 |
| @AmericanBanking | 2 |
| @macondailynews | 2 |
| @TickerReport | 2 |
Recent Tweets for CHRS
 |
@kshahi Are there any big pharmas with a biosimilar void who might want to buy out $CHRS ? Looking out and assuming pipelin… https://t.co/9qjT3VjN2J June 17th 2019, 1:06pm |
 |
@WKRBNews Head-To-Head Comparison: Cortexyme $CRTX vs. Coherus Biosciences $CHRS https://t.co/TTzUILNEZT #markets June 17th 2019, 3:06am |
 |
@macondailynews Coherus Biosciences $CHRS Downgraded by BidaskClub to Buy https://t.co/JjUFE5T6Oe June 15th 2019, 7:06am |
 |
@TrdngDrivatives RT @StockNewsWires: $CHRS $CEIX: Hedge Funds Have Never Been This Bullish On Coherus …: https://t.co/MOYbzbVA88 June 14th 2019, 6:06pm |
 |
@StockNewsWires $CHRS $CEIX: Hedge Funds Have Never Been This Bullish On Coherus …: https://t.co/MOYbzbVA88 June 14th 2019, 6:06pm |
 |
@Gambiste1 RT @kshahi: $CHRS run up til earnings next month, then positive earnings surprise, then continuation upwards and onwards. June 14th 2019, 5:06pm |
|
@Gambiste1 RT @ZG121015: $CHRS https://t.co/XC09NPaHC6 June 14th 2019, 5:06pm |
|
@kshahi $CHRS run up til earnings next month, then positive earnings surprise, then continuation upwards and onwards. June 14th 2019, 3:06pm |
 |
@ChartMill $CHRS is expected to show a strong growth in EPS. In the coming 2 years, the EPS will grow by 64.45% yearly..… https://t.co/opupf1x9hv June 14th 2019, 1:06pm |
|
@macondailynews Barclays Initiates Coverage on Coherus Biosciences $CHRS https://t.co/FTS8OOBTsM June 14th 2019, 10:06am |
 |
@TickerReport Coherus Biosciences $CHRS Downgraded by BidaskClub https://t.co/8ueNchyI7l June 14th 2019, 8:06am |
 |
@ZG121015 $CHRS https://t.co/XC09NPaHC6 June 13th 2019, 8:06pm |
 |
@harnek Major milestones in the biosimilar story, ~20 approvals thus far Biosimilar pure-play $CHRS Coherus breakeven this… https://t.co/UpPskaplOt June 13th 2019, 2:06pm |
 |
@stevedoc22 @larrywabrams @caitlinnowens Not biased reporting. $CHRS -- Udenyca is 2/3 the cost of Neulasta Onpro - a savings o… https://t.co/TZe4Ih8OQk June 13th 2019, 1:06pm |
 |
@WeekHerald Coherus Biosciences $CHRS Lowered to Buy at BidaskClub https://t.co/AGBoQVeobr June 13th 2019, 7:06am |
|
@TickerReport Comparing Coherus Biosciences $CHRS and Cortexyme $CRTX https://t.co/exhr5fwHFy June 12th 2019, 6:06pm |
 |
@MaisaCorp $CHRS Barclays Initiates Coverage on Coherus BioSciences With Overweight Rating and $30 PT June 11th 2019, 3:06pm |
|
@kshahi $CHRS https://t.co/Sq1S1ESgIP June 11th 2019, 10:06am |
 |
@AmericanBanking Barclays Initiates Coverage on Coherus Biosciences $CHRS https://t.co/ASznrG7hJt #stocks June 11th 2019, 8:06am |
 |
@firsttomarkets Coherus Biosciences Inc Initiated Coverage by Barclays Capital (Ranked 33rd) to Overweight with $30PT $CHRS #CHRS https://t.co/65mrWY139z June 11th 2019, 7:06am |
 |
@Briefingcom $CHRS: Barclays starts at Overweight June 11th 2019, 6:06am |
 |
@AnalystWire Barclays Starts Coherus Biosciences $CHRS at Overweight https://t.co/3KXHWLkLVQ June 11th 2019, 2:06am |
 |
@stockmktgenius $CHRS Coherus BioSciences, Inc. #LeaderPullBack Close: 17.26 Liq: $11M https://t.co/PM5S1zW6Uw June 10th 2019, 8:06pm |
 |
@OlympiaReport Coherus Biosciences Inc $CHRS Receives $28.33 Consensus PT from Analysts https://t.co/WnJG02sd2T June 10th 2019, 5:06pm |
 |
@TradeFlags TD BUY $CHRS at 17.91, Supp 17.91 Resis 20.56 R15 HiLo 75% T1Y 29 buy 1.7 fwdPE -111.9 DIV N/A #Coherus Bi #stocks… https://t.co/iM2hAlMLwd June 7th 2019, 10:06pm |
 |
@larrywabrams @kshahi $CHRS audio of Jeffries presentation posted Friday June 7. CEO Lanfear very polished speaker. No specific… https://t.co/eW24HYlo6I June 7th 2019, 9:06am |
|
@larrywabrams @kshahi $CHRS was scheduled to present at Jefferies Tuesday June 5th at 10 AM ET and post audio on website. Well,… https://t.co/NcIcEkbbEK June 6th 2019, 11:06pm |
 |
@ZolmaxNews Zacks: Analysts Anticipate Coherus Biosciences Inc $CHRS Will Post Earnings of -$0.21 Per Share https://t.co/4TkBJnP4mD June 5th 2019, 5:06pm |
|
@kshahi From Jeffries fireside chat this morning, $CHRS looks to break even this year. Based on "area under the curve" calc… https://t.co/m7dVbASSux June 5th 2019, 3:06pm |
 |
@ConsumerFeed Coherus Biosciences Inc $CHRS Given Average Recommendation of “Buy” by Analysts https://t.co/KrxyCt7Pps June 5th 2019, 8:06am |
|
@AmericanBanking Coherus Biosciences Inc $CHRS Given Average Rating of “Buy” by Brokerages https://t.co/5WCjAvJnWS #stocks June 5th 2019, 8:06am |
|
@kshahi Hope $CHRS updates weekly unit shipment numbers tomorrow at Jeffries conference. If trends continue, likely looking at significant upside. June 4th 2019, 6:06pm |
 |
@StockTexts $CHRS Coherus BioSciences, Inc. SEC Filing: Form 4 https://t.co/3F74fWyXLc June 4th 2019, 5:06pm |
|
@kshahi @larrywabrams @caitlinnowens This is a sign that $CHRS is making serious inroads with Udenyca. $AMGN now getting ne… https://t.co/hQ5PEZfZ0u June 4th 2019, 11:06am |
|
@larrywabrams @caitlinnowens @axios Shoddy reporting on $AMGN Neulasta vs $CHRS Udencya. Failed to consider Neulasta now availab… https://t.co/MGq6D08qxP June 4th 2019, 3:06am |
|
@larrywabrams [email protected]? Shoddy reporting on $AMGN Neulasta vs $CHRS Udencya. Failed to consider Neulasta now available as… https://t.co/6ZR31lodI8 June 4th 2019, 3:06am |
 |
@TranscriptDaily -$0.21 Earnings Per Share Expected for Coherus Biosciences Inc $CHRS This Quarter https://t.co/TeIUL73i6X June 3rd 2019, 12:06pm |
 |
@InsiderAlertsIA $CHRS: New Insider Filing on President & CEO DENNIS M LANFEAR: https://t.co/CsDIhrQUxZ June 3rd 2019, 6:06am |
 |
@dailypoliticaln Coherus Biosciences Inc $CHRS CEO Dennis M. Lanfear Sells 32,398 Shares https://t.co/8EQ3VMLNaI June 3rd 2019, 4:06am |
|
@ConsumerFeed Coherus Biosciences Inc $CHRS CEO Dennis M. Lanfear Sells 32,398 Shares https://t.co/evoE74arux June 1st 2019, 11:06am |
|
@WKRBNews Analysts Expect Coherus Biosciences Inc $CHRS to Announce -$0.21 Earnings Per Share https://t.co/vSoGNZlOBl #markets June 1st 2019, 5:06am |
|
@ConsumerFeed Coherus Biosciences CEO Dennis Lanfear Sells $631,437.02 in $CHRS https://t.co/S6VpZVfGSJ June 1st 2019, 3:06am |
 |
@stocknewstimes Insider Selling: Coherus Biosciences Inc $CHRS CEO Sells 32,398 Shares of Stock https://t.co/CDxLVOwabI May 31st 2019, 11:05pm |
 |
@SleekMoneycom Insider Selling: Coherus Biosciences Inc $CHRS CEO Sells 32,398 Shares of Stock https://t.co/gWJARu2c3D #investing May 31st 2019, 11:05pm |
|
@AmericanBanking Coherus Biosciences Inc $CHRS CEO Sells $631,437.02 in Stock https://t.co/wSgsNSkrAD #stocks May 31st 2019, 11:05pm |
 |
@insiderbuyings $CHRS new insider selling: 32398 shares. https://t.co/lh65m3bsZq May 31st 2019, 9:05pm |
|
@StockTexts $CHRS Coherus BioSciences, Inc. SEC Filing: Form 4 https://t.co/9ZR2wByBlU May 31st 2019, 8:05pm |
 |
@fintel_io Insider Lanfear Dennis M reports selling 32,398 shares of $CHRS for a total cost of $631,281.51 https://t.co/TTwdcF7M6M May 31st 2019, 8:05pm |
 |
@confcalltran Coherus BioSciences, Inc.'s President %26 CEO just disposed of 32,398 shares https://t.co/flztAViobz $CHRS May 31st 2019, 8:05pm |
 |
@RTFilingsStocks Lanfear Dennis M files Form 4 for $CHRS Sold 32398 shares Price range: $19.4852-19.4852 Transaction Dates: 5/30/201… https://t.co/E6Sf48Zm6U May 31st 2019, 8:05pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2019. All rights reserved.